Trials / Completed
CompletedNCT03821870
Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity
Predictive Value of In-vitro Anti-cancer Therapy Sensitivity Testing on Tumoroids From Patients With Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (actual)
- Sponsor
- Vejle Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It will be investigated whether it is possible to predict the effect or lack of effect of first-line treatment by analysing cancer cells from the individual patient receiving standard first line treatment. Also, the feasibility of selecting second-line therapy based on pre-treatment biopsies will be investigated. Cells from pancreatic cancer will be grown in the laboratory to form small, circulating tumors and adjacent tissue, so called tumoroids. The tumoroids will then be exposed to different pre-specified anticancer drugs to hopefully reveal sensitivity or lack of sensitivity in the specific patient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Inditreat | Tumoroid formation and drug sensitivity analysis |
| DRUG | Experimental drug | Second line treatment based on drug sensitivity analysis |
Timeline
- Start date
- 2019-02-25
- Primary completion
- 2021-12-31
- Completion
- 2023-02-22
- First posted
- 2019-01-30
- Last updated
- 2023-05-01
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03821870. Inclusion in this directory is not an endorsement.